Canada approves generic semaglutide from Dr. Reddy’s, a G7 first enabled by Novo Nordisk’s lapsed CAD$250 patent

Ozempic is by far the best-selling drug in Canada, with $2.9 billion in sales in 2025, more than three times the next best-selling drug. More than a million Canadians are currently on it. And it is going generic. Health Canada has authorized Dr. Reddy’s Laboratories’ generic semaglutide injection, making Canada the first G7 country to… The post Canada approves generic semaglutide from Dr. Reddy’s, a G7 first enabled by Novo Nordisk’s lapsed CAD$250 patent appeared first on Drug Discovery and Development.

Continue reading →